Motus gi holdings publishes positive results from a european study of the second generation pure-vu system in improving visualization for colonoscopy in patients with a history of poor bowel preparation

Fort lauderdale, fla., jan. 30, 2024 (globe newswire) -- motus gi holdings, inc. (nasdaq: mots, or “motus gi” or “the company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation pure-vu system in a manuscript titled, “an intraprocedural bowel cleansing system for difficult-to-prepare patients—a multicenter prospective feasibility study,” in the peer-reviewed journal, united european gastroenterology (uge). the company's pure-vu system is an fda-approved and ce-certified bowel cleansing system (bcs) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing.
MOTS Ratings Summary
MOTS Quant Ranking